Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma
Status:
Completed
Trial end date:
2016-12-03
Target enrollment:
Participant gender:
Summary
Phase 1(a & b): To evaluate the side effects and determine the best dose of oral ACY-1215 as
monotherapy, and also in combination with bortezomib and dexamethasone in patients with
relapsed or relapsed/refractory multiple myeloma.
Phase 2a: To determine the objective response rate of oral ACY-1215 in combination with
bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple
myeloma.